Here are the 10-Q quarterly reports from XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XOMAP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XOMAP filings page.
XOMA Royalty Corporation reported Q1 2026 total income and revenues of $12.3 million, down from $15.9 million a year earlier as revenue from contracts with customers declined, partly offset by higher income from purchased receivables under the effective interest rate method.
Operating expenses rose to $12.8 million from $10.0 million, driven mainly by higher general and administrative costs and amortization of intangible assets, resulting in an operating loss of $0.5 million. Gains on acquisitions and investment income lifted net income to $4.5 million, compared with $2.4 million in Q1 2025. Basic earnings per share available to common stockholders were $0.18, with diluted earnings per share of $0.17.
XOMA ended the quarter with $138.7 million in cash, cash equivalents, and restricted cash and total assets of $271.9 million. Total liabilities were $159.0 million, including current and long-term debt of about $102.8 million, while stockholders’ equity increased to $92.9 million. Management concluded existing liquidity is sufficient to fund planned operations for at least one year.
XOMA Royalty Corporation is a biotech royalty aggregator, recently reincorporated to Nevada in May 2025. As of June 30, 2025 total assets were $223,456 thousand and total unrestricted and restricted cash and cash equivalents were $78,485 thousand. Management concluded its cash balance is sufficient to fund planned operations, commitments, and contractual obligations for at least one year.
For the three months ended June 30, 2025 total income and revenues were $13,129 thousand and net income was $9,191 thousand, compared with net income of $15,985 thousand in the prior-year quarter. For the six months ended June 30, 2025 total income and revenues were $29,041 thousand and net income was $11,558 thousand. Income from operations was $4,603 thousand for the quarter versus an operating loss of $10,079 thousand in the comparable prior quarter. Stockholders' equity increased to $72,435 thousand from $61,902 thousand at December 31, 2024.
The company paid $20,614 thousand for a BioInvent contract-based intangible asset during the period, recorded long-term debt of $102,201 thousand and convertible preferred stock of $20,019 thousand. The Company reclassified its Series X Convertible Preferred Stock as mezzanine (temporary) equity and restated comparative balances, which management judged immaterial.